{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:54:17Z","timestamp":1793192057000,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCLC patients after first-line immunotherapy and chemotherapy in real-life settings. Association between rwPFS and TNT, two candidate surrogate endpoints (SE), with OS was assessed. This retrospective multi-center study uses data from patients included in the Epidemio-Strategy Medico-Economic program with mNSCLC over 2015\u20132019. The impact of treatment on rwPFS\/OS was evaluated with Cox models. Individual-level associations between SE and OS were estimated with an iterative multiple imputation approach and joint survival models. The population included 5294 patients (63\u00a0years median age). Median OS in immunotherapy group was 16.4\u00a0months (95%CI\u2009[14.1\u2013NR]) and was higher than in chemotherapy group (11.6\u00a0months; 95%CI\u2009[11.0\u201312.2]). Improved OS was observed for the immunotherapy group after 3\u00a0months for subjects with performance status 0\u20131 (HR\u2009=\u20090.59; 95%CI\u2009[0.42\u20130.83], p\u2009&lt;\u20090.01). The associations between rwPFS and TNT with OS were close (<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\uptau$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mi>\u03c4<\/mml:mi>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula>=0.57). Results emphasized a survival improvement with immunotherapy for patients in good health condition. There was moderate evidence of individual-level association between candidate SE and OS.<\/jats:p>","DOI":"10.1038\/s41598-023-36623-1","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T10:02:33Z","timestamp":1686650553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting"],"prefix":"10.1038","volume":"13","author":[{"given":"Yaniss","family":"Belaroussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Bouteiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Bellera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Perol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mathoulin-P\u00e9lissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"30","key":"36623_CR1","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.2217\/fon-2019-0348","volume":"15","author":"JC Simeone","year":"2019","unstructured":"Simeone, J. C., Nordstrom, B. L., Patel, K. & Klein, A. B. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world US setting. Fut. Oncol. Lond. Engl. 15(30), 3491\u20133502 (2019).","journal-title":"Fut. Oncol. Lond. Engl."},{"issue":"19","key":"36623_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823\u201333 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"36623_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","volume":"18","author":"JR Brahmer","year":"2017","unstructured":"Brahmer, J. R. et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 18(12), 1600\u20131609 (2017).","journal-title":"Lancet Oncol."},{"issue":"10183","key":"36623_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet Lond. Engl. 393(10183), 1819\u201330 (2019).","journal-title":"Lancet Lond. Engl."},{"issue":"7","key":"36623_CR5","doi-asserted-by":"publisher","first-page":"vii56","DOI":"10.1093\/annonc\/mds226","volume":"23","author":"S Peters","year":"2012","unstructured":"Peters, S. et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(7), vii56-64 (2012).","journal-title":"Ann. Oncol."},{"issue":"15","key":"36623_CR6","doi-asserted-by":"publisher","first-page":"TPS9101","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS9101","volume":"35","author":"HJ West","year":"2017","unstructured":"West, H. J. et al. IMpower132: A phase III clinical program\u20141L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. J. Clin. Oncol. 35(15), TPS9101\u2013TPS9101 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"36623_CR7","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288\u2013301 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"36623_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078\u201392 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"18_suppl","key":"36623_CR9","doi-asserted-by":"publisher","first-page":"LBA9000","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000","volume":"36","author":"RM Jotte","year":"2018","unstructured":"Jotte, R. M. et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J. Clin. Oncol. 36(18_suppl), LBA9000\u2013LBA9000 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"36623_CR10","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040\u201351 (2018).","journal-title":"N. Engl. J. Med."},{"key":"36623_CR11","unstructured":"Savina M. Surrogate Endpoints for Overall Survival in Cancer Randomized Controlled Trials [Internet] [phdthesis]. Universit\u00e9 de Bordeaux; 2017 [cit\u00e9 1 avr 2020]. https:\/\/tel.archives-ouvertes.fr\/tel-01865829."},{"issue":"22","key":"36623_CR12","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1002\/cncr.32383","volume":"125","author":"S Khozin","year":"2019","unstructured":"Khozin, S. et al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer 125(22), 4019\u201332 (2019).","journal-title":"Cancer"},{"issue":"1","key":"36623_CR13","first-page":"26","volume":"1","author":"LR Pilz","year":"2012","unstructured":"Pilz, L. R., Manegold, C. & Schmid-Bindert, G. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?. Transl. Lung Cancer Res. 1(1), 26\u201335 (2012).","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"36623_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","volume":"15","author":"M Savina","year":"2017","unstructured":"Savina, M. et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study. BMC Med. 15(1), 78 (2017).","journal-title":"BMC Med."},{"issue":"8","key":"36623_CR15","doi-asserted-by":"publisher","first-page":"e0135673","DOI":"10.1371\/journal.pone.0135673","volume":"10","author":"C-LJ Teng","year":"2015","unstructured":"Teng, C.-L.J., Wang, C.-Y., Chen, Y.-H., Lin, C.-H. & Hwang, W.-L. Optimal sequence of irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer: A population-based observational study. PloS One 10(8), e0135673 (2015).","journal-title":"PloS One"},{"key":"36623_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-015-2027-x","volume":"15","author":"C Liang","year":"2015","unstructured":"Liang, C. et al. The treatment patterns, efficacy, and safety of nab (\u00ae)-paclitaxel for the treatment of metastatic breast cancer in the United States: Results from health insurance claims analysis. BMC Cancer 15, 1019 (2015).","journal-title":"BMC Cancer"},{"issue":"2","key":"36623_CR17","first-page":"236","volume":"23","author":"C-C Chen","year":"2017","unstructured":"Chen, C.-C. et al. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or Carfilzomib. J. Manag. Care Spec. Pharm. 23(2), 236\u2013246 (2017).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"11","key":"36623_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","volume":"61","author":"L Chudley","year":"2012","unstructured":"Chudley, L. et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol. Immunother. CII 61(11), 2161\u20132170 (2012).","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"36623_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.11.014","volume":"123","author":"M Savina","year":"2018","unstructured":"Savina, M. et al. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. Crit. Rev. Oncol. Hematol. 123, 21\u201341 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"36623_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 17(4), 343\u2013346 (1996).","journal-title":"Control. Clin. Trials"},{"issue":"6","key":"36623_CR21","first-page":"1887","volume":"45","author":"J Textor","year":"2016","unstructured":"Textor, J., van der Zander, B., Gilthorpe, M. S., Liskiewicz, M. & Ellison, G. T. Robust causal inference using directed acyclic graphs: The R package \u201cdagitty\u201d. Int. J. Epidemiol. 45(6), 1887\u201394 (2016).","journal-title":"Int. J. Epidemiol."},{"issue":"4","key":"36623_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","volume":"20","author":"EF Schisterman","year":"2009","unstructured":"Schisterman, E. F., Cole, S. R. & Platt, R. W. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiol. Camb. Mass 20(4), 488\u2013495 (2009).","journal-title":"Epidemiol. Camb. Mass"},{"issue":"3","key":"36623_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46(3), 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res."},{"issue":"30","key":"36623_CR24","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin, P. C. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat. Med. 35(30), 5642\u201355 (2016).","journal-title":"Stat. Med."},{"issue":"27","key":"36623_CR25","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1002\/sim.5874","volume":"32","author":"M Schemper","year":"2013","unstructured":"Schemper, M., Kaider, A., Wakounig, S. & Heinze, G. Estimating the correlation of bivariate failure times under censoring. Stat. Med. 32(27), 4781\u201390 (2013).","journal-title":"Stat. Med."},{"issue":"16","key":"36623_CR26","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1002\/sim.8162","volume":"38","author":"CL Sofeu","year":"2019","unstructured":"Sofeu, C. L., Emura, T. & Rondeau, V. One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints. Stat. Med. 38(16), 2928\u201342 (2019).","journal-title":"Stat. Med."},{"key":"36623_CR27","unstructured":"Sofeu C. D\u00e9veloppement de m\u00e9thodes pour la validation de crit\u00e8res de substitution en survie\u202f: m\u00e9ta-analyses de cancer [Internet] [These de doctorat]. Bordeaux; 2019 [cit\u00e9 19 ao\u00fbt 2020]. http:\/\/www.theses.fr\/2019BORD0383."},{"key":"36623_CR28","unstructured":"Cancer du poumon\u202f: points-cl\u00e9s - Cancer du poumon [Internet]. [cit\u00e9 22 juin 2021]. https:\/\/www.e-cancer.fr\/Patients-et-proches\/Les-cancers\/Cancer-du-poumon\/Les-points-cles."},{"issue":"10","key":"36623_CR29","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","volume":"11","author":"T-YD Cheng","year":"2016","unstructured":"Cheng, T.-Y.D. et al. The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. J. Thorac. Oncol. 11(10), 1653\u201371 (2016).","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"36623_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/cpt.1658","volume":"107","author":"BK Beaulieu-Jones","year":"2020","unstructured":"Beaulieu-Jones, B. K. et al. Examining the use of real-world evidence in the regulatory process. Clin. Pharmacol. Ther. 107(4), 843\u2013852 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"36623_CR31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1634\/theoncologist.2018-0307","volume":"24","author":"S Khozin","year":"2019","unstructured":"Khozin, S. et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist 24(5), 648\u201356 (2019).","journal-title":"Oncologist"},{"issue":"7","key":"36623_CR32","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/cam4.2806","volume":"9","author":"K Amrane","year":"2020","unstructured":"Amrane, K. et al. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 \u226550% in a multicenter real-life cohort: The PEMBREIZH study. Cancer Med. 9(7), 2309\u20132316 (2020).","journal-title":"Cancer Med."},{"issue":"1","key":"36623_CR33","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41598-019-40748-7","volume":"9","author":"P Song","year":"2019","unstructured":"Song, P., Zhang, J., Shang, C. & Zhang, L. Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1\/PD-L1 inhibitors. Sci. Rep. 9(1), 4278 (2019).","journal-title":"Sci. Rep."},{"issue":"6","key":"36623_CR34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s10637-019-00843-y","volume":"37","author":"M Tamiya","year":"2019","unstructured":"Tamiya, M. et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: A multicenter retrospective cohort study (HOPE-001). Investig. New Drugs 37(6), 1266\u20131273 (2019).","journal-title":"Investig. New Drugs"},{"key":"36623_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lungcan.2019.05.005","volume":"133","author":"D Ksienski","year":"2019","unstructured":"Ksienski, D. et al. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice. Lung Cancer 133, 110\u20136 (2019).","journal-title":"Lung Cancer"},{"issue":"18","key":"36623_CR36","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2217\/imt-2019-0177","volume":"11","author":"V Velcheti","year":"2019","unstructured":"Velcheti, V. et al. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS \u226550%) metastatic NSCLC at US oncology practices. Immunotherapy 11(18), 1541\u20131554 (2019).","journal-title":"Immunotherapy"},{"issue":"11","key":"36623_CR37","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","volume":"69","author":"A Cortellini","year":"2020","unstructured":"Cortellini, A. et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u2265 50%. Cancer Immunol. Immunother. 69(11), 2209\u201321 (2020).","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"36623_CR38","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.21037\/tlcr-21-15","volume":"10","author":"F Facchinetti","year":"2021","unstructured":"Facchinetti, F., Di Maio, M., Perrone, F. & Tiseo, M. First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis. Transl. Lung Cancer Res. 10(6), 2917\u20132936 (2021).","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"36623_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cllc.2021.02.001","volume":"22","author":"N Frost","year":"2021","unstructured":"Frost, N. et al. Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (\u2265 50%) NSCLC: Real-world results with special focus on PS \u2265 2, brain metastases, and steroids. Clin. Lung Cancer 22(5), 411\u2013422 (2021).","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"36623_CR40","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/j.cllc.2020.09.017","volume":"22","author":"G Mountzios","year":"2021","unstructured":"Mountzios, G. et al. Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy. Clin. Lung Cancer 22(2), e180\u2013e192 (2021).","journal-title":"Clin. Lung Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36623-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36623-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36623-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T10:11:32Z","timestamp":1686651092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36623-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36623"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-36623-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9584"}}